Logo image of GMTX

GEMINI THERAPEUTICS INC (GMTX) Stock Fundamental Analysis

USA - NASDAQ:GMTX - US36870G1058 - Common Stock

1.35 USD
0 (0%)
Last: 12/29/2022, 8:00:02 PM
1.32 USD
-0.03 (-2.22%)
After Hours: 12/29/2022, 8:00:02 PM
Fundamental Rating

3

GMTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. While GMTX has a great health rating, there are worries on its profitability. GMTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GMTX has reported negative net income.
In the past year GMTX has reported a negative cash flow from operations.
GMTX Yearly Net Income VS EBIT VS OCF VS FCFGMTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 -20M -40M -60M

1.2 Ratios

GMTX has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GMTX Yearly ROA, ROE, ROICGMTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GMTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GMTX Yearly Profit, Operating, Gross MarginsGMTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for GMTX has been increased compared to 1 year ago.
Compared to 1 year ago, GMTX has a worse debt to assets ratio.
GMTX Yearly Shares OutstandingGMTX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 10M 20M 30M 40M
GMTX Yearly Total Debt VS Total AssetsGMTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 50M 100M

2.2 Solvency

GMTX has an Altman-Z score of 21.03. This indicates that GMTX is financially healthy and has little risk of bankruptcy at the moment.
GMTX has a Altman-Z score of 21.03. This is amongst the best in the industry. GMTX outperforms 94.57% of its industry peers.
There is no outstanding debt for GMTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 21.03
ROIC/WACCN/A
WACCN/A
GMTX Yearly LT Debt VS Equity VS FCFGMTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 0 50M -50M 100M

2.3 Liquidity

GMTX has a Current Ratio of 71.49. This indicates that GMTX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of GMTX (71.49) is better than 99.53% of its industry peers.
A Quick Ratio of 71.49 indicates that GMTX has no problem at all paying its short term obligations.
GMTX has a better Quick ratio (71.49) than 99.53% of its industry peers.
Industry RankSector Rank
Current Ratio 71.49
Quick Ratio 71.49
GMTX Yearly Current Assets VS Current LiabilitesGMTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 50M 100M

More info and screens

1

3. Growth

3.1 Past

GMTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.64%, which is quite impressive.
EPS 1Y (TTM)29.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.41%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GMTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.85% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y81.97%
EPS Next 2Y36.14%
EPS Next 3Y23.09%
EPS Next 5Y12.85%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GMTX Yearly EPS VS EstimatesGMTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GMTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GMTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GMTX Price Earnings VS Forward Price EarningsGMTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GMTX Per share dataGMTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

GMTX's earnings are expected to grow with 23.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.14%
EPS Next 3Y23.09%

More info and screens

0

5. Dividend

5.1 Amount

GMTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GEMINI THERAPEUTICS INC

NASDAQ:GMTX (12/29/2022, 8:00:02 PM)

After market: 1.32 -0.03 (-2.22%)

1.35

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2022-08-11/bmo
Earnings (Next)03-08 2023-03-08
Inst Owners5.62%
Inst Owner Change0%
Ins Owners8.83%
Ins Owner Change0%
Market Cap58.45M
Revenue(TTM)N/A
Net Income(TTM)-43421000
Analysts43.33
Price Target1.53 (13.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.57%
Min EPS beat(2)21.57%
Max EPS beat(2)21.57%
EPS beat(4)2
Avg EPS beat(4)8.99%
Min EPS beat(4)-13.81%
Max EPS beat(4)21.57%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-1.81
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0
BVpS2.41
TBVpS2.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 71.49
Quick Ratio 71.49
Altman-Z 21.03
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.41%
EPS Next Y81.97%
EPS Next 2Y36.14%
EPS Next 3Y23.09%
EPS Next 5Y12.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-14131.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-14114.3%
OCF growth 3YN/A
OCF growth 5YN/A

GEMINI THERAPEUTICS INC / GMTX FAQ

What is the ChartMill fundamental rating of GEMINI THERAPEUTICS INC (GMTX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to GMTX.


What is the valuation status for GMTX stock?

ChartMill assigns a valuation rating of 3 / 10 to GEMINI THERAPEUTICS INC (GMTX). This can be considered as Overvalued.


What is the profitability of GMTX stock?

GEMINI THERAPEUTICS INC (GMTX) has a profitability rating of 1 / 10.


How financially healthy is GEMINI THERAPEUTICS INC?

The financial health rating of GEMINI THERAPEUTICS INC (GMTX) is 8 / 10.